share_log

Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab

RegeneronはERS 2024で呼吸器疾患管理の科学的な革新とリーダーシップを強調し、DupixentとItepekimabを特集しています

Benzinga ·  08/26 01:48
  • 20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Data from landmark Phase 3 trials for Dupixent in COPD reinforce exacerbation reduction and improvement in lung function compared to placebo, and provide new assessments on health-related quality of life across patient subgroups
  • Additional presentations spotlight a novel asthma imaging study showing the early impact of Dupixent on clinical remission, airway remodeling and mucus plugging starting at 4 weeks, as well as data from investigational therapy itepekimab in former smokers with COPD
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする